Navigation Links
Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
Date:3/7/2011

id Dr. Henner. "Aerie is a leader in the field of ophthalmology with their portfolio of innovative glaucoma products, and we feel privileged to contribute to that success."

"Despite the fact that glaucoma is a progressive disease, there has not been a drug with a new mechanism of action approved in the glaucoma field since the mid-nineties," said Dr. Mehra. "Patients often need several drugs to control their disease, and physicians have limited options with these older mechanisms. We believe that AR-12286's new MOA, strong efficacy, excellent tolerability, and once daily dosing can provide real value to patients at risk of losing their vision."

In addition to Aerie's lead program, the company is also pursuing several pipeline programs including, AR-13324, the first of a novel glaucoma drug class discovered at Aerie with a unique dual-mechanism. A platform technology of conjunctival inserts is also being advanced to the clinic.  This innovative technology is targeting a mechanism for long-term delivery of drugs that has the potential to offer efficacy comparable to daily prescription eye drops, while addressing the therapeutic challenges involved with patient compliance in glaucoma therapy.

About Aerie PharmaceuticalsAerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. The company is located in Research Triangle Park, NC and in Bridgewater, NJ. All technology of the company is based on internal R&D, which establishes a strong IP portfolio. The innovative glaucoma pipeline includes the lead clinical product AR-12286, a selective Rho-kinase (ROCK) inhibitor designed to lower IOP by improving outflow of fluid via the trabecular pathway. This first-in-class product has successfully completed Phase 2 clinical studies and is ready to be advanced to Phase 3.  AR-13324, an IND candidate with a unique dual mechanism of ac
'/>"/>

SOURCE Aerie Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Pharmaceuticals Selects BDO USA as its Auditor
2. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
4. Endo Pharmaceuticals Launches FORTESTAâ„¢ (Testosterone) Gel for Topical Use Class III for Adult Men in the U.S. With Low Testosterone
5. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
7. Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
8. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
9. Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
10. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
11. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... CVS Caremark Corporation (NYSE: CVS ), today announced ... ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... Net revenues increased 12.5% to a record $26.7 billion ... Retail Pharmacy segment revenues increased 3.8%, with same ...
... Bellicum Pharmaceuticals, Inc. today announced publication in ... results using a new therapy that demonstrated rapid and ... Inducible Apoptosis as a Safety Switch for Adoptive Cell ... ™ technology to eliminate donor T cells causing ...
Cached Medicine Technology:CVS Caremark Reports Third Quarter Results 2CVS Caremark Reports Third Quarter Results 3CVS Caremark Reports Third Quarter Results 4CVS Caremark Reports Third Quarter Results 5CVS Caremark Reports Third Quarter Results 6CVS Caremark Reports Third Quarter Results 7CVS Caremark Reports Third Quarter Results 8CVS Caremark Reports Third Quarter Results 9CVS Caremark Reports Third Quarter Results 10CVS Caremark Reports Third Quarter Results 11CVS Caremark Reports Third Quarter Results 12CVS Caremark Reports Third Quarter Results 13CVS Caremark Reports Third Quarter Results 14CVS Caremark Reports Third Quarter Results 15Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 2Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 3Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 4
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... Wash., June 11 Following a two-year clinical ... , Stayhealthy introduced their next generation body composition ... The technology accurately measures body composition, comes in ... a home use individual device, to a commercial ...
... , , Continued Market Share Increase Combined with ... SAN BRUNO, Calif., June 11 Cord Blood Registry ... stem cells from umbilical cord blood, reported solid revenue growth in ... 2008. Earnings for the quarter showed even stronger gains due ...
... ... help parents combat teen drug use, is now available from Bartell Drugs , ... Seattle, CA (Vocus) June 11, 2009 -- HairConfirm, a new ... from Bartell Drugs. The kit detects drug use for up to 90 days by analyzing ...
... ... of British Heart week (8-15th June), Dr Jav Nazemi - CEO of Igennus, ... condition led to the start of his business and the omega-3 EPA formula, ... pence per tub sold this week to the Children,s Heart Federation, in order ...
... ... is a struggle for women of all ages. Despite the turmoil of ... for symptomatic relief of menstrual and menopausal woes. Garden of Life, Inc., ... women of all ages a natural way to balance hormones with the ...
... 10 The following statement was issued Wednesday, June ... Jessie M. Pavlinac, following a press conference by U.S. ... restaurant menu labeling to be included in the Senate,s ... health-care reform legislation. , , "The American Dietetic ...
Cached Medicine News:Health News:New Stayhealthy Body Composition Technology Announced at Microsoft's Connected Health Conference 2Health News:New Stayhealthy Body Composition Technology Announced at Microsoft's Connected Health Conference 3Health News:Cord Blood Registry Maintains Solid Growth in First Quarter 2009 2Health News:Cord Blood Registry Maintains Solid Growth in First Quarter 2009 3Health News:New Home Drug Hair Test Kit Now Available from Bartell Drugs; ,HairConfirm Detects 90-Day Drug Use & Usage Frequency 2Health News:Omega-3 EPA: Treatment for a Heart Condition 2Health News:Omega-3 EPA: Treatment for a Heart Condition 3Health News:Omega-3 EPA: Treatment for a Heart Condition 4Health News:Omega-3 EPA: Treatment for a Heart Condition 5Health News:Omega-3 EPA: Treatment for a Heart Condition 6Health News:MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3™ Healthy Hormones™ 2Health News:MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3™ Healthy Hormones™ 3Health News:MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3™ Healthy Hormones™ 4Health News:Statement by American Dietetic Association Supporting Scientifically Valid, Informative Restaurant Labeling as Part of Health Reform 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: